RE:RE:RE:RE:RE:Jd..this is directly to you...kayacker i have no issue with"....you and i both know that most of my comments have been accurate and fair...." Accurate and fair? Uh huh. Here's what you
said last year....
"....maybe pharma doesn't really want or possibly need, what bioasis does or doesn't have?
up to now, pharma seem to be satisfied with whatever results they have for transporting therapeutics across the bbb (no agreement with bioasis is the gauge)...." How clueless is that.
"....not cause i said so but cause we're still waiting to go into the clinic with no money...." Into the clinic? Too funny. Back in 2015, when you predicted a 2016 Q2 buyout, here's what I
said in response....
"....A buyout by Q2 2016? I give that about a 1% chance. IMO it's unlikely without clinical data, and I don't expect that until 2017...." So which one of us understood the need for clinical data before we make decent money on this. (Hint: not you).
"....so you go and carry on with your "share price doesn't matter"...." And you carry on making stuff up. I've never said "share price doesn't matter". In fact, here I
said in 2015....
"....Yo Jekyl, that's pretty funny. You whine and complain every time the share price goes down a few cents. Of course share price matters...." I just don't get obsessed with daily ups and downs. I know we'll trade in a range until we get significant deals and move to clinical trials.
"....these things take longer than expected...." Another thing you've never understood. Go look up the "planning fallacy" and learn something. Maybe you'll get a wee bit of insight into why you've misjudged the timing so badly over the years.
"....why don't you explain to me just how the internal programs are going to advance given the current cash position...." Of course they aren't. Duh. The Company is moving forward with two internal programs, Scarpa on MPSII and Trastuzamab Phase Zero team in Australia. When BTI gets to the point where we actually need the cash, I'm sure we'll hear about what option they go with.